List of Excipients in Branded Drug ZONISAMIDE

Generic Drugs Containing ZONISAMIDE

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY LLC dba Vangard Labs	zonisamide	0615-8266	CELLULOSE, MICROCRYSTALLINE
NCS HealthCare of KY LLC dba Vangard Labs	zonisamide	0615-8266	FERRIC OXIDE RED
NCS HealthCare of KY LLC dba Vangard Labs	zonisamide	0615-8266	GELATIN
NCS HealthCare of KY LLC dba Vangard Labs	zonisamide	0615-8266	HYDROGENATED CASTOR OIL

What are the Most Frequently-Used Excipients in ZONISAMIDE?

# Of NDCs	Excipient
12	ALCOHOL
14	AMMONIA
12	BUTYL ALCOHOL
54	CELLULOSE, MICROCRYSTALLINE

Zonisamide Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Zonisamide is a mature, orally administered antiseizure drug with limited active-ingredient exclusivity and substantial generic competition. Commercial differentiation depends on dosage-form performance, pediatric usability, adherence, taste masking, excipient tolerability, and manufacturing economics rather than new-molecule protection.

The strongest opportunities are liquid and multiparticulate products, orally disintegrating or rapidly dispersing dosage forms, sprinkle capsules, and formulations that reduce dosing friction for pediatric, geriatric, and dysphagic patients. Zonisamide has high oral bioavailability, so excipient development should prioritize content uniformity, dissolution consistency, palatability, physical stability, and dose flexibility rather than aggressive solubility enhancement.

What is the regulatory and commercial status of zonisamide?

Zonisamide is an orally active sulfonamide antiseizure medicine marketed in the United States as Zonegran capsules and through generic products. The FDA approved Zonegran under NDA 020789 for adjunctive therapy in adults with partial seizures. Zonisamide is also used in clinical practice for seizure disorders outside the original adjunctive-therapy indication, subject to applicable labeling and prescribing rules. [1]

Attribute	Zonisamide
Drug class	Antiseizure medicine; sulfonamide derivative
Primary dosage form	Immediate-release capsule
Reference product	Zonegran
U.S. NDA	020789
Original U.S. sponsor	Dainippon Pharmaceutical Co., now associated with Sumitomo Pharma
Typical strengths	25 mg, 50 mg, and 100 mg capsules
Route	Oral
Generic status	Multiple generic products
FDA market position	Mature product with generic competition
Main commercial constraint	Low differentiation of conventional capsules

The reference product uses hard-gelatin capsules with inactive ingredients that include common pharmaceutical excipients such as microcrystalline cellulose, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate. Capsule-shell colorants and titanium dioxide have varied across manufacturers and jurisdictions. Product-specific labeling must be used when evaluating exact qualitative and quantitative composition. [2]

When did zonisamide lose exclusivity and patent protection?

Zonisamide no longer has a conventional small-molecule exclusivity profile that would block routine generic competition. The original product has been commercially exposed to generic substitution for many years.

FDA exclusivity and Orange Book position

The principal U.S. commercial facts are:

Issue	Assessment
New chemical entity exclusivity	Expired
Pediatric exclusivity	Not a current barrier to generic entry
Conventional capsule generic entry	Established
Paragraph IV threat to the original capsule	Commercially less significant than formulation differentiation
Orange Book strategy	Any relevant listed patents must be checked against the current FDA Orange Book for the specific NDA
Current competitive focus	Product quality, supply, price, dosage-form convenience, and channel access

Because zonisamide is an old small molecule, new patent value would generally need to come from a genuinely differentiated formulation, manufacturing process, delivery system, or clinically meaningful method of use. A patent claiming only routine excipient substitution is vulnerable to obviousness and lack-of-enablement challenges.

What physicochemical properties drive the zonisamide excipient strategy?

Zonisamide is a crystalline, low-molecular-weight sulfonamide compound with high oral absorption under conventional immediate-release conditions. Its commercial formulation does not require a complex lipid or depot delivery system.

The formulation implications are direct:

1. Immediate-release capsules can rely on conventional powder-fill technology.
2. Excipient selection should support rapid and reproducible dissolution.
3. Liquid products need suspension stabilization or a suitable solubilization approach.
4. Taste masking is important because pediatric and geriatric products may expose the drug directly to the oral cavity.
5. The formulation must address dose uniformity across low and high strengths.
6. Hygroscopicity, electrostatic behavior, powder flow, and capsule-fill accuracy can affect manufacturing performance.

A high-cost amorphous dispersion, nanosuspension, or self-emulsifying system would require evidence of a meaningful clinical or manufacturing benefit. For standard seizure therapy, the stronger commercial case is usually better administration and dosing flexibility.

Which excipients are suitable for zonisamide capsules?

A conventional zonisamide capsule can use a compact excipient system with a clear manufacturing rationale.

Formulation function	Candidate excipients	Commercial rationale
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Controls fill weight and supports dose uniformity
Glidant	Colloidal silicon dioxide	Improves powder flow and fill consistency
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports encapsulation and ejection
Wetting aid	Sodium lauryl sulfate or a lower-risk surfactant	Can improve wetting where dissolution data justify use
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Useful for tablets, pellets, or rapidly dispersing systems
Binder	Povidone, hydroxypropyl cellulose	Supports granulation and multiparticulate manufacture
Capsule shell	Gelatin or hypromellose	Enables vegetarian, religious, and formulation-specific positioning
Opacifier or colorant	Titanium dioxide or approved alternatives	Supports appearance and light protection where needed

The principal development risk is overengineering. Zonisamide capsules already have a simple administration profile. A formulation should demonstrate measurable improvement in dissolution, content uniformity, stability, manufacturability, or patient use.

Excipient compatibility risks

Zonisamide contains a sulfonamide functional group. The active ingredient itself is associated with clinically important sulfonamide-related warnings, including serious hypersensitivity reactions. Excipients do not generally reproduce the pharmacology of sulfonamide antibiotics, but product developers must evaluate excipient hypersensitivity, residual impurities, and labeling requirements separately. [3]

Priority compatibility studies should cover:

• Drug-excipient chemical interaction.
• Moisture-mediated degradation.
• Capsule-shell brittleness and cross-linking.
• Lubricant impact on dissolution.
• Surfactant compatibility and impurity control.
• Colorant and titanium dioxide regulatory status by market.
• Microbial control for aqueous or semisolid products.
• Container-closure interaction.

What zonisamide liquid formulations offer commercially?

A ready-to-use oral suspension or solution has the clearest patient-centered opportunity. Capsules are poorly suited to children, patients with swallowing difficulties, and patients requiring nonstandard titration.

A liquid product can offer:

• Weight-based pediatric dosing.
• 10 mg/mL, 20 mg/mL, or other flexible concentration options.
• Easier dose titration.
• Administration through enteral feeding tubes.
• Reduced capsule opening and manipulation.
• Improved adherence in patients with dysphagia.

Suspension versus solution

A true solution can provide the best dose uniformity if adequate drug solubility and chemical stability are achieved. If the required concentration is not practical, a suspension is more realistic.

A suspension strategy would typically evaluate:

• Suspending agents such as microcrystalline cellulose and carboxymethylcellulose systems.
• Wetting agents.
• Buffer selection.
• Sweeteners and flavor systems.
• Preservatives where permitted and justified.
• Antimicrobial effectiveness.
• Redispersibility after storage.
• Dose uniformity at the beginning, middle, and end of the container.
• Compatibility with oral syringes and feeding tubes.

Commercial development must avoid relying solely on pharmacy-compounded suspension data. A finished product needs validated stability, microbial control, dosing accuracy, and labeling for storage and handling. FDA guidance for oral liquid products emphasizes concentration, dosing-device performance, and product quality. [4]

What taste-masking approaches are available for zonisamide?

Taste masking is likely to be a central technical issue in pediatric zonisamide development. A liquid, chewable tablet, orally disintegrating tablet, or sprinkle product may expose the drug to taste receptors.

Potential approaches include:

Polymer coating

Drug particles or pellets can be coated with ethylcellulose, methacrylate copolymers, hypromellose, or other film-forming systems. The coating must suppress immediate taste release without delaying therapeutic dissolution after swallowing.

Ion exchange or complexation

Ion-exchange resins and cyclodextrin systems can reduce free drug exposure in the mouth. Their suitability depends on zonisamide’s ionization behavior, loading efficiency, release profile, and regulatory acceptability.

Lipid or wax barriers

Lipid-based coating can reduce wetting and taste release. The approach requires careful control of particle size, dissolution, content uniformity, and storage stability.

Flavor and sweetener systems

Flavoring alone is unlikely to be adequate if the active ingredient has a strong or persistent taste. It can be used with coating, complexation, or a viscous suspension vehicle.

A patentable product would need data showing a defined taste-masking effect, a reproducible manufacturing process, and dissolution that remains within the required immediate-release profile.

What formulation patents could protect zonisamide products?

The original zonisamide molecule and conventional capsule product are mature assets. New patent value is more likely in the following categories:

Patent category	Potential claim focus	Strength
Pediatric liquid	Concentration, vehicle, preservative system, stability	Moderate if clinically useful and non-obvious
Taste-masked particles	Coating composition, particle architecture, release profile	Moderate to strong if technically specific
Orally disintegrating tablet	Porosity, excipient ratio, disintegration and taste performance	Moderate
Sprinkle capsule	Pellets, granules, tube compatibility, food administration	Moderate
Modified release	Release-controlling matrix or multiparticulate system	Potentially strong but commercially uncertain
Manufacturing process	Controlled granulation, particle engineering, coating process	Moderate if process-specific
Combination product	Zonisamide with another active ingredient	Dependent on clinical evidence
Method of use	New patient population or dosing regimen	Requires credible clinical support

Broad claims covering "zonisamide and a pharmaceutically acceptable excipient" would face significant validity risk. Stronger claims would define measurable parameters such as particle-size distribution, coating weight gain, dissolution limits, sedimentation behavior, redispersibility, dose uniformity, or stability period.

How many patents cover zonisamide?

The relevant patent count depends on the jurisdiction, claim family, prosecution history, and whether expired patents are included. A raw worldwide count would overstate commercial protection because it may include continuations, national-stage filings, abandoned applications, and expired rights.

For commercial analysis, patents should be divided into four groups:

1. Original compound patents, which are generally expired.
2. Reference-product formulation patents, if listed for the specific NDA.
3. Third-party formulation and delivery patents.
4. New development patents covering liquids, taste masking, multiparticulates, or manufacturing.

The decisive question is not the number of published documents. It is whether an unexpired, enforceable claim reads on the proposed commercial product in the target market.

What generic entry risks exist for zonisamide?

Generic competition is already established for conventional immediate-release capsules. A new entrant therefore faces price pressure and limited brand differentiation.

Generic risks by product type

Product	Generic risk	Differentiation opportunity
Standard 25 mg, 50 mg, and 100 mg capsules	High	Low
Capsule with alternative shell	High	Low unless tied to a specific patient need
Ready-to-use oral suspension	Moderate	High
Taste-masked pediatric granules	Moderate	High
Orally disintegrating tablet	Moderate	Moderate to high
Modified-release product	Lower initially	High development and regulatory burden
Combination product	Product-specific	Requires clinical and IP support

A liquid product could face an abbreviated application, 505(b)(2) pathway, or another jurisdiction-specific route depending on the formulation and regulatory strategy. The regulatory pathway will affect the ability to rely on reference-product data, the need for clinical bridging, and the value of formulation patents. [5]

Which companies are competing in zonisamide?

Competition is divided between the reference-product franchise, generic capsule manufacturers, and potential specialty-formulation developers.

The principal commercial entities include:

• Sumitomo Pharma and affiliated rights holders associated with Zonegran.
• Generic manufacturers that market zonisamide capsules in the United States and other regulated markets.
• Specialty pharmaceutical companies developing pediatric liquids, sprinkle products, and adherence-oriented formulations.
• Contract development and manufacturing organizations with multiparticulate coating, oral-liquid, and capsule-filling capabilities.

The highest-value partner is unlikely to be a low-cost capsule manufacturer. It is more likely to be a company with pediatric commercial infrastructure, oral-liquid regulatory experience, or a differentiated delivery platform.

What licensing opportunities exist for zonisamide?

Licensing opportunities are strongest where a partner controls one of four assets:

1. A validated pediatric liquid with stability and dosing-device data.
2. A taste-masking platform that can support immediate release.
3. A multiparticulate or sprinkle technology compatible with food and enteral administration.
4. A regional commercial network in pediatric neurology or hospital pharmacy.

A licensing transaction should distinguish between rights to the active ingredient, rights to a formulation patent, regulatory filing ownership, manufacturing know-how, and territory-specific commercialization rights. For a mature generic molecule, royalties based only on sales may be difficult to justify unless the product has a protected dosage form or clear formulary advantage.

What manufacturing and intellectual-property barriers matter most?

The practical barriers are technical and operational:

• Achieving uniform low-dose distribution in a bulk powder.
• Controlling powder flow during capsule filling.
• Preventing segregation between zonisamide and diluent.
• Maintaining suspension uniformity throughout use.
• Producing coated particles with narrow coating-weight variation.
• Demonstrating rapid release after taste masking.
• Validating syringe and feeding-tube dosing.
• Managing preservative and microbial-control requirements.
• Securing reliable supply of specialized coating polymers and functional excipients.
• Establishing freedom to operate around delivery-platform patents.

For a conventional capsule, these barriers are manageable and rarely create durable market protection. For a pediatric liquid or taste-masked multiparticulate product, they can support both regulatory differentiation and patentable process know-how.

How does zonisamide compare with competing antiseizure products?

Product	Common dosage-form options	Excipient opportunity	Competitive position
Zonisamide	Capsules; potential liquid, ODT, sprinkle formats	High for pediatric usability	Mature generic market
Topiramate	Tablets, capsules, sprinkle capsules, oral solution in some markets	Strong benchmark for pediatric delivery	Broad generic competition
Levetiracetam	Tablets, oral solution, injection	Strong liquid and hospital presence	Highly competitive
Lamotrigine	Tablets, chewable/dispersible tablets	Strong dose-flexibility model	Titration and rash risk affect use
Oxcarbazepine	Tablets, suspension	Direct liquid-formulation comparator	Pediatric liquid precedent
Clobazam	Tablets, oral suspension in some markets	Controlled-substance and formulation considerations	Specialty positioning

Zonisamide’s main formulation gap is the absence of a broadly dominant, convenient pediatric dosage form comparable with established oral solutions or sprinkle products in competing antiseizure categories.

What is the revenue exposure and commercial upside?

Conventional zonisamide capsules are exposed to generic price erosion. Revenue upside from a reformulation depends on whether the product can secure:

• Pediatric or hospital formulary adoption.
• A higher-value specialty-pharmacy position.
• Better adherence or reduced administration errors.
• Coverage under a differentiated National Drug Code.
• Patent or regulatory protection.
• Geographic markets with limited generic liquid competition.

The commercial case is strongest for a product that solves a documented administration problem. A modestly improved capsule is unlikely to command durable pricing power. A stable, palatable, ready-to-use liquid with an oral syringe and feeding-tube compatibility has a more credible value proposition.

Key Takeaways

• Zonisamide is a mature generic antiseizure drug with limited value in conventional capsule reformulation.
• The strongest excipient opportunities are pediatric liquids, taste-masked multiparticulates, sprinkle capsules, and rapidly dispersing dosage forms.
• Microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, disintegrants, coating polymers, suspending agents, and flavor systems are the main development toolset.
• Taste masking must preserve immediate-release dissolution and dose uniformity.
• New patent value depends on specific formulation architecture, process controls, and measurable performance.
• A ready-to-use oral suspension could address pediatric dosing, dysphagia, enteral administration, and titration needs.
• Generic risk is high for standard capsules and lower for differentiated dosage forms.
• The most attractive licensing partners are companies with pediatric commercialization, oral-liquid manufacturing, or multiparticulate technology.
• FDA Orange Book and Drugs@FDA records should control any product-specific patent or regulatory conclusion. [1, 2]

FAQs

Can zonisamide be formulated as an oral solution?

Yes, but the feasibility depends on concentration, solubility, chemical stability, taste, preservative requirements, and dose uniformity. A suspension may be more practical than a true solution at commercially useful concentrations.

Which excipients are most important for zonisamide taste masking?

Coating polymers, ion-exchange resins, cyclodextrins, lipid barriers, viscosity modifiers, sweeteners, and flavor systems are the principal options. The final choice depends on dissolution and sensory data.

Is a zonisamide liquid likely to receive patent protection?

Potentially. Protection is more credible for a defined vehicle, concentration, stabilization system, taste-masked particle structure, or manufacturing process than for a generic liquid dosage form.

Does zonisamide require a solubility-enhancing formulation?

Usually not for conventional immediate-release oral therapy because standard products achieve effective systemic exposure. Solubility enhancement becomes more relevant if a high-concentration liquid or rapid-dissolution product is required.

What is the best commercial dosage form for pediatric zonisamide?

A palatable, ready-to-use oral suspension with an accurate oral syringe is the most direct opportunity. Taste-masked granules or sprinkle capsules could provide a second differentiated platform for children who cannot swallow capsules.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Zonegran NDA 020789. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.). Zonegran prescribing information. FDA.

4. U.S. Food and Drug Administration. (2015). Dosage delivery devices for orally ingested OTC liquid drug products. FDA.

5. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.